EGFR and cancer: Various oncogenic pathways have been reported to affect expression of MHC-I, β2M, and other APM components in cancer, including the MAPK-, epidermal growth factor receptor (EGFR), HER2, c-MYC, and n-MYC pathway [182,183,184,185,186,187].